ARTICLE | Emerging Company Profile
Oral route for HAE
Why Pharvaris believes its oral compound can stand out in the crowded HAE field
May 31, 2018 11:43 PM UTC
The team behind Firazyr icatibant has reunited to develop an oral version of the drug that could give hereditary angioedema patients the alternative to injectables they’ve been asking for.
Pharvaris B.V. brings together team members responsible for developing Firazyr at Jerini AG with veterans of rare disease company Prosensa Holding N.V. to develop a compound that could improve ease of use for HAE patients by treating the disease both prophylactically and on-demand. All six marketed HAE drugs require parenteral delivery. None act as both a prophylactic and a therapy for acute attacks. Five act by replacing the C1 esterase inhibitor or inhibiting KLKB1, while Shire plc’s Firazyr is a BDKRB2 antagonist. ...